|Application ||WB, IHC|
|Calculated MW||22960 Da|
|Other Names||FAS-associated death domain protein, FAS-associating death domain-containing protein, Mediator of receptor induced toxicity, Protein FADD, Fadd, Mort1|
|Target/Specificity||A synthetic peptide corresponding to residues near the N-term of human FADD was used as immunogen.|
|Format||50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||FADD Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Apoptotic adaptor molecule that recruits caspase-8 or caspase-10 to the activated Fas (CD95) or TNFR-1 receptors. The resulting aggregate called the death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation. Active caspase-8 initiates the subsequent cascade of caspases mediating apoptosis (By similarity). Involved in interferon-mediated antiviral immune response, playing a role in the positive regulation of interferon signaling (By similarity).|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Fas-associating protein with death domain (FADD) is an adaptor protein involved in the apoptosis induced by Fas and TNF-R1, and mitogen induced cell proliferation (1). FADD consists of death domain (DD) at the C-terminal and death effector domain (DED) at the N-terminal (2). DD interacts with Fas and TNF-R1, which exposes the DED portion on the FADD. Unmasked DED binds to the DED of pro-caspase-8, which activates the cysteine protease cascade (3). The development of autoimmune lymphoproliferative (lpr) diseases has been linked to inactivation of Fas-FADD interaction (4). Also, the deficiency in FADD can inhibit TRAIL-induced cell apoptosis.
1. Imtiyaz HZ et al, I J. Biol. Chem., Vol. 280, Issue 36, 31360-31367, 2005
2. Chinnaiyan AM et al. Cell 81, 505
3. Boldin MP et al, Cell 85, 803
4. Cohen PL et al. Annu. Rev. Immunol. 9, 243
If you have any additional inquiries please email technical services at firstname.lastname@example.org.